Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies
Open accessThe DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index; 63 of the 117 sources its claims cite were checked for support.
Abstract
Platinum-based cancer therapy remains a cornerstone of first-line treatment for several solid tumours such as ovarian, testicular, and non-small cell lung cancers, where it has received regulatory approval as both monotherapy and combination regimens. However, the inevitable emergence of resistance has necessitated extensive preclinical and clinical efforts to develop rational platinum-based combinations. The most appealing candidates for combination therapy are those that offer additive and/or synergistic effects without undesirable overlapping toxicities. Whilst early strategies focussed on co-administration with cytotoxic chemotherapies, recent advances have shifted towards combinations with targeted therapies and immunotherapies, offering improved efficacy and durability of response. In this review, we provide a comprehensive analysis of recent clinical trials evaluating platinum-based combination strategies (excluding radiotherapy) and give an overview of trial concepts that will lead to more refined therapies for cancer. We also highlight emerging dual-drug codelivery nanosystems, platinum-based antibody-drug conjugates (ADCs), and multi-targeted platinum compounds with promising preclinical and/or clinical evidence. Beyond traditional drug pairings, the improved design strategies of new platinum compounds such as their incorporation into ADCs offer enhanced targeting and reactivity. Whilst promising preclinical examples like trastuzumab-Pt(II) and cetuximab-C8Pt(IV) bring optimism to combinatorial approaches, significant challenges including stability and controlled payload release remain to be addressed before clinical translation. By integrating advances in molecular profiling and rational drug development, platinum-based therapies continue to evolve, offering renewed optimism for overcoming drug resistance and improving patient outcomes, although challenges such as biomarker identification, toxicity management, and treatment costs remain to be fully addressed.
Overview
CoChat Summary
TL;DR
This review summarizes recent clinical and preclinical strategies to overcome platinum resistance by combining platinum drugs with cytotoxic agents, targeted therapies, immunotherapies, and emerging delivery/design platforms. It argues that the most promising gains come from rational combinations that preserve or improve efficacy while avoiding overlapping toxicity, with biomarker-guided patient selection increasingly emphasized.
Key findings
- The review states that current and completed trials examined platinum drugs with cytotoxic agents (37%), targeted therapies (44%), and immunotherapies (18%).
- In ovarian cancer, carboplatin/paclitaxel remains a standard backbone, with phase III trials reporting mPFS of 16.8–20.7 months and mOS up to 57.4 months; carboplatin/PLD improved mPFS to 11.3 vs. 9.4 months over carboplatin/paclitaxel in partially platinum-sensitive disease.
- For platinum-resistant biology, the paper notes ~85% of ovarian cancer patients eventually develop resistance after an initial response, with low response rates to further chemotherapy (<15%), PFS of 3–4 months, and median survival of less than 1 year.
- Several combinations showed clinically meaningful activity: adavosertib plus carboplatin/paclitaxel improved mPFS to 7.9 vs. 7.3 months; veliparib plus cisplatin/etoposide improved mOS to 10.2 vs. 8.9 months; pembrolizumab plus cisplatin/gemcitabine improved mOS to 12.7 vs. 10.9 months; DCVAC/OvCa plus carboplatin/gemcitabine improved mOS to 35.5 vs. 22.1 months.
Methods
- Narrative review of platinum-based combination strategies, focusing on recent clinical studies, “the majority of which have been completed since 2019,” and excluding radiotherapy.
- The paper compiles data across cancer types from clinical trials and selected preclinical studies; it reports the clinical data in Supplementary Table S1.
- Main analysis is qualitative/comparative: it groups combinations into cytotoxic, targeted, immunotherapy, and other emerging strategies, and compares efficacy, tolerability, and resistance-related rationale.
Limitations
- The paper states that many combinations still face overlapping toxicity, resistance, biomarker uncertainty, and cost challenges.
- It also notes that several promising strategies remain preclinical or have not yet entered clinical trials, including platinum-based ADCs and multi-targeted platinum compounds.
- Evident from the text: this is a review rather than an original trial, so conclusions depend on heterogeneous studies with varying cancer types, regimens, endpoints, and patient selection criteria.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




![Fig. 5 Platinum-based ADCs as new strategies for specific tumour-targeting. a Platinum compounds are encapsulated in carrier molecules linked to mAbs to enhance drug delivery and targeting. b Schematic illustration of the preparation of an anti-tissue factor (TF) antibody fragment-antigen binding (Fab') conjugated to polymeric micelles containing an active complex of oxaliplatin, (1,2diaminocyclohexane)platinum(II) (DACHPt) (DACHPt/m). Reprinted from [77], Copyright 2015, with permission from Elsevier. Schematic illustration of the method for preparing oxaliplatin (L-OH)-loaded liposomes linked to either (c) whole cetuximab (CTX) or (d) CTX-Fab’ fragments to their surface. Reprinted from [78], Copyright 2015, with permission from Elsevier](https://figures.cochat.ai/paper-figures/4109f9953d574a5a97abe9ccd4bec6e4/advances-in-platinum-based-cancer-therapy-overcoming-platinum-resistance-through-figure-5.jpg)

Verification
Claims the paper makes
56 Valid · 1 Not valid · 42 Not checked · 16 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, single-drug therapy is typically inadequate for patients with advanced disease, leading to rapid disease progression and poor clinical outcomes [17].”
§ Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies > Introduction Cancer remains a burden on society due to its high mortality and morbidity, as well as the economic strain it places on healthcare systems [1, 2]. Amongst the established chemotherapeutic agents, metallodrugs have been extensively used for cancer therapy where they offer versatile electronic and unique structural features [3–5]. The tuning of the metal, ligand, or metal–ligand interaction provides exceptional structural diversity and novel chemistry for drug design, resulting in a greater range of functions and unique mechanisms of action. In contrast to organic drugs, metallodrugs are often 'prodrugs' that convert into active forms once they enter the body or when they reach the desired target. This activation frequently involves the displacement or dissociation of one or more labile ligands, the opening of chelate rings, or a change in the oxidation state of the metal and/or ligands. Additionally, metallodrugs can also be selectively activated by external stimuli such as light, radiation, ultrasound, or heat upon reaching the target site. The antiproliferative effects of cisplatin (cis-diamminedichloroplatinum(II)) (Fig. 1) were discovered in 1965 by Barnett Rosenberg with the aid of serendipity, where his group observed that the inhibition of bacterial growth was not caused by electric fields, but rather by the platinum (Pt) compound that was released from the electrodes [6]. In 1978, the FDA granted regulatory approval for cisplatin to be used for the treatment of a variety of solid malignancies, making it one of the most successful therapeutic metallodrugs to date [6, 7]. Cisplatin exerts its cytotoxic effects through a complex interplay of molecular mechanisms, primarily by coordinating DNA to form platinum–DNA adducts, resulting in DNA damage, mitochondrial dysfunction, reactive oxygen species (ROS) generation, modulation of cell death pathways and subsequent apoptosis [7]. These multifaceted effects underscore the potency of cisplatin as a chemotherapy agent. However, despite being effective in numerous cases, cisplatin is linked to significant off-target toxicity, including nephrotoxicity, ototoxicity, and neurotoxicity [8]. Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10]. Given the early success of cisplatin and to overcome its drawbacks, second- and third-generation cisplatin analogues were developed. One of the most successful platinum analogues is carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)) (Fig. 1) which was reported by Cleare and Hoeschele in 1973, and then gained FDA approval in 1989 [11]. Shortly after this, oxaliplatin (1R,2R-diaminocyclohexane oxalatoplatinum(II)) (Fig. 1) received European approval in 1999 and FDA approval in 2002 [12]. These second-generation platinum-based metallodrugs were developed with specific goals such as reducing toxicity, improving stability, and broadening the range of activity compared to cisplatin. Other drugs of a similar design were subsequently developed including nedaplatin, lobaplatin, and heptaplatin (Fig. 1), which have each gained approval in Japan, China, and South Korea, respectively [13]. Other than these drugs, satraplatin (Fig. 1) was developed, exciting great interest due to its high oral availability such that it can be administered in pill form, greatly improving patient convenience and reducing health care costs [14, 15]. Satraplatin has proven that overcoming the initially limiting conditions for platinum drug design (platinum(II) and cis-conformation) will help fuel the design of new lead compounds with improved functionality. Anti-cancer monotherapies, whether broadly active cytotoxics or even the most effective molecularly targeted drugs, have limited ability to induce long-lasting clinical responses, as drug resistance is common [16]. Moreover, single-drug therapy is typically inadequate for patients with advanced disease, leading to rapid disease progression and poor clinical outcomes [17]. As a result, combination therapies of two or more drugs now dominate modern cancer medicine. Specifically, additive and/or synergistic relationships can convert less effective single-drug treatments into regimens with robust anti-tumour activity [17]. Drug synergy is achieved when the combined effect of two or more drugs is greater than that predicted by their individual potencies where this has the advantages of: (1) increasing drug efficacy; (2) significantly lower therapeutic doses for each individual drug compared to when they are administered alone; (3) minimising the development of drug resistance or relapse; (4) achieving high cancer selectivity (cancer cell killing without affecting normal cells); and (5) expanding the range of treatment-responsive cancers [18, 19]. Many reviews have provided comprehensive perspectives on the use of platinum metallodrugs given as monotherapies [20, 21]. In this review, we specifically focus on the use of these platinum metallodrugs in combinatorial therapy to treat various cancers, considering the potential benefits compared to the risks in such approaches. We present examples of investigations into such combinations, with a significant emphasis on recent clinical studies, the majority of which have been completed since 2019. The primary endpoints of these clinical trials were highlighted, and the available clinical data is reported in Supplementary Table S1. Current and completed trials have examined platinum drugs with various therapies, including cytotoxic agents (37%), targeted therapies (44%), and immunotherapies (18%) (Fig. 2).
What the sources say
- Partly supportedcites [17] Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–43. 10.18632/oncotarget.16723. 28410237 PMC5514969 sourceExperimental — accuracy not yet measured
The Background (page unavailable) says monotherapy is generally less effective than combination therapy and more susceptible to drug resistance. The Abstract notes low survival rates for most metastatic cancers, but the paper does not establish that single-drug therapy typically causes rapid progression and poor clinical outcomes specifically in patients with advanced disease. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Anti-cancer monotherapies, whether broadly active cytotoxics or even the most effective molecularly targeted drugs, have limited ability to induce long-lasting clinical responses, as drug resistance is common [16].”
§ Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies > Introduction Cancer remains a burden on society due to its high mortality and morbidity, as well as the economic strain it places on healthcare systems [1, 2]. Amongst the established chemotherapeutic agents, metallodrugs have been extensively used for cancer therapy where they offer versatile electronic and unique structural features [3–5]. The tuning of the metal, ligand, or metal–ligand interaction provides exceptional structural diversity and novel chemistry for drug design, resulting in a greater range of functions and unique mechanisms of action. In contrast to organic drugs, metallodrugs are often 'prodrugs' that convert into active forms once they enter the body or when they reach the desired target. This activation frequently involves the displacement or dissociation of one or more labile ligands, the opening of chelate rings, or a change in the oxidation state of the metal and/or ligands. Additionally, metallodrugs can also be selectively activated by external stimuli such as light, radiation, ultrasound, or heat upon reaching the target site. The antiproliferative effects of cisplatin (cis-diamminedichloroplatinum(II)) (Fig. 1) were discovered in 1965 by Barnett Rosenberg with the aid of serendipity, where his group observed that the inhibition of bacterial growth was not caused by electric fields, but rather by the platinum (Pt) compound that was released from the electrodes [6]. In 1978, the FDA granted regulatory approval for cisplatin to be used for the treatment of a variety of solid malignancies, making it one of the most successful therapeutic metallodrugs to date [6, 7]. Cisplatin exerts its cytotoxic effects through a complex interplay of molecular mechanisms, primarily by coordinating DNA to form platinum–DNA adducts, resulting in DNA damage, mitochondrial dysfunction, reactive oxygen species (ROS) generation, modulation of cell death pathways and subsequent apoptosis [7]. These multifaceted effects underscore the potency of cisplatin as a chemotherapy agent. However, despite being effective in numerous cases, cisplatin is linked to significant off-target toxicity, including nephrotoxicity, ototoxicity, and neurotoxicity [8]. Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10]. Given the early success of cisplatin and to overcome its drawbacks, second- and third-generation cisplatin analogues were developed. One of the most successful platinum analogues is carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)) (Fig. 1) which was reported by Cleare and Hoeschele in 1973, and then gained FDA approval in 1989 [11]. Shortly after this, oxaliplatin (1R,2R-diaminocyclohexane oxalatoplatinum(II)) (Fig. 1) received European approval in 1999 and FDA approval in 2002 [12]. These second-generation platinum-based metallodrugs were developed with specific goals such as reducing toxicity, improving stability, and broadening the range of activity compared to cisplatin. Other drugs of a similar design were subsequently developed including nedaplatin, lobaplatin, and heptaplatin (Fig. 1), which have each gained approval in Japan, China, and South Korea, respectively [13]. Other than these drugs, satraplatin (Fig. 1) was developed, exciting great interest due to its high oral availability such that it can be administered in pill form, greatly improving patient convenience and reducing health care costs [14, 15]. Satraplatin has proven that overcoming the initially limiting conditions for platinum drug design (platinum(II) and cis-conformation) will help fuel the design of new lead compounds with improved functionality. Anti-cancer monotherapies, whether broadly active cytotoxics or even the most effective molecularly targeted drugs, have limited ability to induce long-lasting clinical responses, as drug resistance is common [16]. Moreover, single-drug therapy is typically inadequate for patients with advanced disease, leading to rapid disease progression and poor clinical outcomes [17]. As a result, combination therapies of two or more drugs now dominate modern cancer medicine. Specifically, additive and/or synergistic relationships can convert less effective single-drug treatments into regimens with robust anti-tumour activity [17]. Drug synergy is achieved when the combined effect of two or more drugs is greater than that predicted by their individual potencies where this has the advantages of: (1) increasing drug efficacy; (2) significantly lower therapeutic doses for each individual drug compared to when they are administered alone; (3) minimising the development of drug resistance or relapse; (4) achieving high cancer selectivity (cancer cell killing without affecting normal cells); and (5) expanding the range of treatment-responsive cancers [18, 19]. Many reviews have provided comprehensive perspectives on the use of platinum metallodrugs given as monotherapies [20, 21]. In this review, we specifically focus on the use of these platinum metallodrugs in combinatorial therapy to treat various cancers, considering the potential benefits compared to the risks in such approaches. We present examples of investigations into such combinations, with a significant emphasis on recent clinical studies, the majority of which have been completed since 2019. The primary endpoints of these clinical trials were highlighted, and the available clinical data is reported in Supplementary Table S1. Current and completed trials have examined platinum drugs with various therapies, including cytotoxic agents (37%), targeted therapies (44%), and immunotherapies (18%) (Fig. 2).
What the sources say
- Supportedcites [16] Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MFR, et al. Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol. 2022. 10.3389/fonc.2022.891652. 35814435 PMC9262248 source
The Introduction (no page provided) says that many anticancer drugs are effective initially but resistance often develops as treatment progresses. Section 2.1 (no page provided) describes acquired resistance to targeted therapy, while the Conclusions (no page provided) say resistance is responsible for most cancer relapses. Together, these passages support the claim that resistance limits lasting responses to cytotoxic and targeted drugs. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10].”
§ Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies > Introduction Cancer remains a burden on society due to its high mortality and morbidity, as well as the economic strain it places on healthcare systems [1, 2]. Amongst the established chemotherapeutic agents, metallodrugs have been extensively used for cancer therapy where they offer versatile electronic and unique structural features [3–5]. The tuning of the metal, ligand, or metal–ligand interaction provides exceptional structural diversity and novel chemistry for drug design, resulting in a greater range of functions and unique mechanisms of action. In contrast to organic drugs, metallodrugs are often 'prodrugs' that convert into active forms once they enter the body or when they reach the desired target. This activation frequently involves the displacement or dissociation of one or more labile ligands, the opening of chelate rings, or a change in the oxidation state of the metal and/or ligands. Additionally, metallodrugs can also be selectively activated by external stimuli such as light, radiation, ultrasound, or heat upon reaching the target site. The antiproliferative effects of cisplatin (cis-diamminedichloroplatinum(II)) (Fig. 1) were discovered in 1965 by Barnett Rosenberg with the aid of serendipity, where his group observed that the inhibition of bacterial growth was not caused by electric fields, but rather by the platinum (Pt) compound that was released from the electrodes [6]. In 1978, the FDA granted regulatory approval for cisplatin to be used for the treatment of a variety of solid malignancies, making it one of the most successful therapeutic metallodrugs to date [6, 7]. Cisplatin exerts its cytotoxic effects through a complex interplay of molecular mechanisms, primarily by coordinating DNA to form platinum–DNA adducts, resulting in DNA damage, mitochondrial dysfunction, reactive oxygen species (ROS) generation, modulation of cell death pathways and subsequent apoptosis [7]. These multifaceted effects underscore the potency of cisplatin as a chemotherapy agent. However, despite being effective in numerous cases, cisplatin is linked to significant off-target toxicity, including nephrotoxicity, ototoxicity, and neurotoxicity [8]. Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10]. Given the early success of cisplatin and to overcome its drawbacks, second- and third-generation cisplatin analogues were developed. One of the most successful platinum analogues is carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)) (Fig. 1) which was reported by Cleare and Hoeschele in 1973, and then gained FDA approval in 1989 [11]. Shortly after this, oxaliplatin (1R,2R-diaminocyclohexane oxalatoplatinum(II)) (Fig. 1) received European approval in 1999 and FDA approval in 2002 [12]. These second-generation platinum-based metallodrugs were developed with specific goals such as reducing toxicity, improving stability, and broadening the range of activity compared to cisplatin. Other drugs of a similar design were subsequently developed including nedaplatin, lobaplatin, and heptaplatin (Fig. 1), which have each gained approval in Japan, China, and South Korea, respectively [13]. Other than these drugs, satraplatin (Fig. 1) was developed, exciting great interest due to its high oral availability such that it can be administered in pill form, greatly improving patient convenience and reducing health care costs [14, 15]. Satraplatin has proven that overcoming the initially limiting conditions for platinum drug design (platinum(II) and cis-conformation) will help fuel the design of new lead compounds with improved functionality. Anti-cancer monotherapies, whether broadly active cytotoxics or even the most effective molecularly targeted drugs, have limited ability to induce long-lasting clinical responses, as drug resistance is common [16]. Moreover, single-drug therapy is typically inadequate for patients with advanced disease, leading to rapid disease progression and poor clinical outcomes [17]. As a result, combination therapies of two or more drugs now dominate modern cancer medicine. Specifically, additive and/or synergistic relationships can convert less effective single-drug treatments into regimens with robust anti-tumour activity [17]. Drug synergy is achieved when the combined effect of two or more drugs is greater than that predicted by their individual potencies where this has the advantages of: (1) increasing drug efficacy; (2) significantly lower therapeutic doses for each individual drug compared to when they are administered alone; (3) minimising the development of drug resistance or relapse; (4) achieving high cancer selectivity (cancer cell killing without affecting normal cells); and (5) expanding the range of treatment-responsive cancers [18, 19]. Many reviews have provided comprehensive perspectives on the use of platinum metallodrugs given as monotherapies [20, 21]. In this review, we specifically focus on the use of these platinum metallodrugs in combinatorial therapy to treat various cancers, considering the potential benefits compared to the risks in such approaches. We present examples of investigations into such combinations, with a significant emphasis on recent clinical studies, the majority of which have been completed since 2019. The primary endpoints of these clinical trials were highlighted, and the available clinical data is reported in Supplementary Table S1. Current and completed trials have examined platinum drugs with various therapies, including cytotoxic agents (37%), targeted therapies (44%), and immunotherapies (18%) (Fig. 2).
What the sources say
- Not checked — no full text of the sourcecites [9] Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83. 10.1038/onc.2011.384. 21892204 source
- Partly supportedcites [10] Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3):706–21. 10.1124/pr.111.005637. 22659329 PMC3400836 sourceExperimental — accuracy not yet measured
The Introduction reports that patients often respond initially but later relapse as cisplatin resistance reduces treatment effectiveness. The Conclusions describe activation of multiple protective pathways during resistance development. Neither passage establishes that prolonged treatment selects those pathways, and the paper does not state the claimed poor-prognosis outcome. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Specifically, additive and/or synergistic relationships can convert less effective single-drug treatments into regimens with robust anti-tumour activity [17].”
§ Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies > Introduction Cancer remains a burden on society due to its high mortality and morbidity, as well as the economic strain it places on healthcare systems [1, 2]. Amongst the established chemotherapeutic agents, metallodrugs have been extensively used for cancer therapy where they offer versatile electronic and unique structural features [3–5]. The tuning of the metal, ligand, or metal–ligand interaction provides exceptional structural diversity and novel chemistry for drug design, resulting in a greater range of functions and unique mechanisms of action. In contrast to organic drugs, metallodrugs are often 'prodrugs' that convert into active forms once they enter the body or when they reach the desired target. This activation frequently involves the displacement or dissociation of one or more labile ligands, the opening of chelate rings, or a change in the oxidation state of the metal and/or ligands. Additionally, metallodrugs can also be selectively activated by external stimuli such as light, radiation, ultrasound, or heat upon reaching the target site. The antiproliferative effects of cisplatin (cis-diamminedichloroplatinum(II)) (Fig. 1) were discovered in 1965 by Barnett Rosenberg with the aid of serendipity, where his group observed that the inhibition of bacterial growth was not caused by electric fields, but rather by the platinum (Pt) compound that was released from the electrodes [6]. In 1978, the FDA granted regulatory approval for cisplatin to be used for the treatment of a variety of solid malignancies, making it one of the most successful therapeutic metallodrugs to date [6, 7]. Cisplatin exerts its cytotoxic effects through a complex interplay of molecular mechanisms, primarily by coordinating DNA to form platinum–DNA adducts, resulting in DNA damage, mitochondrial dysfunction, reactive oxygen species (ROS) generation, modulation of cell death pathways and subsequent apoptosis [7]. These multifaceted effects underscore the potency of cisplatin as a chemotherapy agent. However, despite being effective in numerous cases, cisplatin is linked to significant off-target toxicity, including nephrotoxicity, ototoxicity, and neurotoxicity [8]. Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10]. Given the early success of cisplatin and to overcome its drawbacks, second- and third-generation cisplatin analogues were developed. One of the most successful platinum analogues is carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)) (Fig. 1) which was reported by Cleare and Hoeschele in 1973, and then gained FDA approval in 1989 [11]. Shortly after this, oxaliplatin (1R,2R-diaminocyclohexane oxalatoplatinum(II)) (Fig. 1) received European approval in 1999 and FDA approval in 2002 [12]. These second-generation platinum-based metallodrugs were developed with specific goals such as reducing toxicity, improving stability, and broadening the range of activity compared to cisplatin. Other drugs of a similar design were subsequently developed including nedaplatin, lobaplatin, and heptaplatin (Fig. 1), which have each gained approval in Japan, China, and South Korea, respectively [13]. Other than these drugs, satraplatin (Fig. 1) was developed, exciting great interest due to its high oral availability such that it can be administered in pill form, greatly improving patient convenience and reducing health care costs [14, 15]. Satraplatin has proven that overcoming the initially limiting conditions for platinum drug design (platinum(II) and cis-conformation) will help fuel the design of new lead compounds with improved functionality. Anti-cancer monotherapies, whether broadly active cytotoxics or even the most effective molecularly targeted drugs, have limited ability to induce long-lasting clinical responses, as drug resistance is common [16]. Moreover, single-drug therapy is typically inadequate for patients with advanced disease, leading to rapid disease progression and poor clinical outcomes [17]. As a result, combination therapies of two or more drugs now dominate modern cancer medicine. Specifically, additive and/or synergistic relationships can convert less effective single-drug treatments into regimens with robust anti-tumour activity [17]. Drug synergy is achieved when the combined effect of two or more drugs is greater than that predicted by their individual potencies where this has the advantages of: (1) increasing drug efficacy; (2) significantly lower therapeutic doses for each individual drug compared to when they are administered alone; (3) minimising the development of drug resistance or relapse; (4) achieving high cancer selectivity (cancer cell killing without affecting normal cells); and (5) expanding the range of treatment-responsive cancers [18, 19]. Many reviews have provided comprehensive perspectives on the use of platinum metallodrugs given as monotherapies [20, 21]. In this review, we specifically focus on the use of these platinum metallodrugs in combinatorial therapy to treat various cancers, considering the potential benefits compared to the risks in such approaches. We present examples of investigations into such combinations, with a significant emphasis on recent clinical studies, the majority of which have been completed since 2019. The primary endpoints of these clinical trials were highlighted, and the available clinical data is reported in Supplementary Table S1. Current and completed trials have examined platinum drugs with various therapies, including cytotoxic agents (37%), targeted therapies (44%), and immunotherapies (18%) (Fig. 2).
What the sources say
- Supportedcites [17] Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–43. 10.18632/oncotarget.16723. 28410237 PMC5514969 source
The Abstract says combining anti-cancer drugs enhances efficacy over monotherapy through synergistic or additive action and can reduce tumour growth. The Background also describes monotherapy as generally less effective than combination therapy. Together, these passages support the paraphrase. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Fluorescence tracking with Cy5.5-labelled Cet-C8Pt(IV) further showed progressive cellular uptake over 6 h.”
§ Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies > Combining platinum-based drugs with targeted therapies > Platinum-based antibody–drug conjugates (ADCs) The advent of antibody–drug conjugate (ADC) has revolutionised cancer therapy by precisely targeting tumour antigens, improving efficacy, reducing drug toxicity, and enhancing the therapeutic window. Thanks to the advances in synthetic chemistry, ADCs have been designed to comprise tumour-targeting mAbs linked to cytotoxic payloads via intricately designed chemical linkers, simultaneously enabling potent effectiveness and precise targeting, thereby expanding the therapeutic index [72]. Mirvetuximab soravtansine is an example of an ADC where the antibody mirvetuximab (anti-folate receptor α, or anti-FRα) is linked to a cytotoxic drug called DM4 (a maytansinoid). In an intriguing approach, carboplatin was examined in combination with mirvetuximab soravtansine in patients with platinum-sensitive ovarian cancer in a phase Ib trial (NCT02606305) [73]. This combination demonstrated clinical benefit and is well tolerated (ORR: 71% and mPFS: 15 months). Whilst most ADCs in the preclinical and clinical developments rely on complex organic molecules, the potential of conjugating metallodrugs to mAbs has been largely neglected. Metallo-based ADCs might reduce the high cost associated with producing targeted chemotherapeutics, as their bioconjugation to mAbs could be simpler compared to cytotoxic payloads derived from organic molecules and natural products (Fig. 4a) [74]. Studies have shown that the conjugation of platinum drugs to trastuzumab via a cathepsin B cleavable dipeptide enhances drug accumulation and enables specific delivery to HER2-positive cancer cells (Fig. 4b) [75]. Trastuzumab-Pt(II) conjugate has been loaded with approximately 6.4 mol of platinum drugs per mole of antibody, retaining a high and selective binding affinity for the HER2 protein and HER2-positive SK-BR-3 breast cancer cells. Compared to oxaliplatin, trastuzumab-Pt(II) conjugate exhibits a higher cellular uptake of platinum drugs with improved in vitro cytotoxicity against SK-BR-3 cells. Similarly, conjugation of a new cytotoxic platinum (IV) prodrug (C8Pt(IV)) with cetuximab (Cet-C8Pt(IV)) also showed excellent tumour targeting in cutaneous squamous cell carcinoma (Fig. 4c) [76]. Compared to free platinum drugs, antibody-platinum (Ab-Pt) conjugates exhibit distinct cellular uptake mechanisms, platinum accumulation profiles, and DNA platination efficiency. Free platinum drugs such as cisplatin and oxaliplatin primarily enter cells via passive diffusion, leading to relatively non-specific intracellular distribution. In contrast, Ab-Pt conjugates are internalised via receptor-mediated endocytosis, enabling more targeted delivery to tumour cells. Experimental studies demonstrate the advantages of this approach. In HER2-positive SK-BR-3 cells, free oxaliplatin showed faster initial uptake, reaching 25 ng Pt per million cells at 4 h, approximately 1.7-fold higher than Herceptin-Pt(II) conjugate [75]. However, after 24 h, platinum accumulation in Herceptin-Pt(II)-treated cells reached 224 ng Pt per million cells, compared to only 67 ng for oxaliplatin-treated cells. This difference highlights the enhanced and sustained cellular uptake conferred by antibody targeting, attributed to the specific interaction between Herceptin and HER2 receptors and subsequent receptor-mediated endocytosis. Similarly, in EGFR-positive epidermoid carcinoma A-431 cells, treatment with a cetuximab-conjugated platinum(IV) prodrug (Cet-C8Pt(IV)) resulted in platinum concentrations 6.83 and 6.58 times higher than free C8Pt(IV) and a non-conjugated C8Pt(IV)/cetuximab mixture, respectively [76]. Competitive inhibition experiments confirmed that Cet-C8Pt(IV) targets EGFR specifically, as platinum uptake was 1.83 times higher in cells without cetuximab pretreatment. Fluorescence tracking with Cy5.5-labelled Cet-C8Pt(IV) further showed progressive cellular uptake over 6 h. Following internalisation, platinum release from Ab-Pt conjugates occur within endosomal or lysosomal compartments, typically triggered by acid-sensitive linkers or enzymatic cleavage. Successful release of the active platinum species is critical for cytosolic escape and subsequent nuclear targeting. Activated platinum species then form DNA adducts, disrupting replication and transcription. However, efficient endosomal escape remains a key factor influencing therapeutic efficacy, as entrapment in endosomes may limit access to nuclear DNA. ADCs have demonstrated high efficacy by offering targeted delivery of cytotoxic drugs to tumours. However, they are limited by the payload they can carry. By integrating antibodies into drug-loaded nanocarriers, the ability of antibodies to deliver a wide range of therapeutic agents is significantly enhanced. Thus, platinum compounds were also encapsulated in carrier molecules bound to mAbs to further improve drug delivery and targeting (Fig. 5a). For instance, Ahn et al. developed an anti-tissue factor (TF) antibody fragment-antigen binding (Fab') conjugated to polymeric micelles containing an active complex of oxaliplatin, (1,2diaminocyclohexane)platinum(II) (DACHPt) (DACHPt/m, Fig. 5b) [77]. DACHPt/m was formed through maleimide-thiol conjugation and was designed to selectively deliver platinum drugs to pancreatic tumours. Notably, DACHPt/m demonstrated rapid cellular internalisation, resulting in enhanced in vitro cytotoxicity and effectively inhibiting the growth of pancreatic tumour xenografts in vivo, surpassing both non-targeted micelles and free drugs. Furthermore, Zalba et al. developed oxaliplatin (L-OH)-loaded liposomes linked to either whole cetuximab (CTX) or CTX-Fab’ fragments to their surface (Fig. 5c, d) [78]. In EGFR-overexpressing cell lines, targeted liposomes achieved up to threefold higher intracellular drug delivery compared to non-targeted liposomes. When tested in a colorectal cancer (CRC) xenograft model, these ADCs significantly enhanced drug delivery, with CTX-Fab’ L-OH-liposomes outperforming CTX-mAb L-OH-liposomes. This, in turn, was more effective than non-targeted liposomes and free drug treatment in mice with CRC. In addition, a novel ADC was synthesised incorporating ferritin-based nanoparticles where mAb Ep1 were conjugated to a single ferritin cage (Hft) encapsulating cisplatin [79]. Compared to cisplatin-containing ferritin nanoparticle alone, which were more effective in inhibiting thymidine incorporation in breast carcinoma than in melanoma cells, the HFt-Pt-Ep1 nanoparticle exhibited higher preference for melanoma cells. A similar preference for melanoma was observed in nude mice xenotransplanted with melanoma and breast carcinoma cells. This study identified the specific combinations and stoichiometric relationships between mAbs and nanoparticle protein cages, leading to the loss of tropism for ubiquitously distributed cellular receptors and the acquisition of lineage-selective binding. Moreover, another study developed oxaliplatin-loaded apoferritin conjugated with panitumumab via a polyethylene glycol (PEG) linker, which was designed to specifically target EGFR-overexpressing cell lines [80]. This ADC efficiently released oxaliplatin, inhibited tumour cell proliferation, and exhibited enhanced accumulation in tumour models with high EGFR expression in vivo. Remarkably, these studies have exhibited promising results, demonstrating that immune-nanocarriers can effectively enhance the therapeutic translational potential of ADCs containing platinum drugs. Due to the promising results obtained in these studies, ongoing efforts are currently underway to develop next-generation platinum-based ADCs.
What the sources say
- Supportedcites [76] Yin X, Zhuang Y, Song H, Xu Y, Zhang F, Cui J, et al. Antibody-platinum (IV) prodrugs conjugates for targeted treatment of cutaneous squamous cell carcinoma. J Pharm Anal. 2024;14(3):389–400. 10.1016/j.jpha.2023.11.002. 38618248 PMC11010626 source
The Results and discussion section (Anti-tumor activity of Cet-C8Pt(IV) in vitro; page not provided) says Cy5.5-labelled Cet-C8Pt(IV) was incubated with A-431 cells for up to 6 h and that cellular fluorescence increased progressively with treatment time. It reports the same trend by flow cytometry and confocal microscopy. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
50 more claims · 21 with their cited sources checked
Create a free account to see all 115 claims and to verify the 13 references still open.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 5
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303 · cited 1×
“Cancer remains a burden on society due to its high mortality and morbidity, as well as the economic strain it places on healthcare systems [1, 2].”
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“In 2011, based on promising results from a clinical trial in melanoma patients, the first ICI therapy ipilimumab, an anti-CTLA-4 mAb, has gained FDA approval [98].”
Cancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 5,689 · cited 1×
“Cancer remains a burden on society due to its high mortality and morbidity, as well as the economic strain it places on healthcare systems [1, 2].”
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537 · cited 3×
“In 1978, the FDA granted regulatory approval for cisplatin to be used for the treatment of a variety of solid malignancies, making it one of the most successful therapeutic metallodrugs to date [6, 7].”
InfluentialA guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154 · cited 1×
“The advent of frontline immunotherapy in clinical trials rapidly changed the treatment landscape, establishing it as the standard of care in some clinical situations [94].”
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726 · cited 1×
“In HNSCC, platinum-based regimens combined with cetuximab remain a standard treat-ment, with the EXTREME regimen achieving mOS of 10.1 months and PFS of 5.6 months (NCT00122460) [132].”
InfluentialMolecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 2×
“Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10].”
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543 · cited 2×
“Specifically, additive and/or synergistic relationships can convert less effective single-drug treatments into regimens with robust anti-tumour activity [17].”
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485 · cited 1×
“1), which have each gained approval in Japan, China, and South Korea, respectively [13].”
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274 · cited 1×
“Notably, paclitaxel (taxane), in combination with either cisplatin or carboplatin, was approved by FDA for treating patients with advanced ovarian cancer after initial surgery [22], and NSCLC [23, 24].”
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751 · cited 1×
“Many reviews have provided comprehensive perspectives on the use of platinum metallodrugs given as monotherapies [20, 21].”
Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., & Yang, S.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052719 · Cited by 1,694
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350 · cited 1×
“Nanocarriers offer several advantages, including enhancing the water solubility of poorly soluble drugs, prolonging their circulation time in the blood, and facilitating drug targeting to tumours [139].”
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Oh, D.-Y., Ruth He, A., Qin, S., Chen, L.-T., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Ah Lee, M., Kitano, M., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200015 · Cited by 1,217 · cited 1×
“In another phase III trial, durvalumab with cisplatin/gemcitabine significantly showed improvements compared to the placebo/chemotherapy group in patients with BTC (24-month OS rate: 24.9% vs. 10.4% and ORR: 26.7% vs. 18.7%; NCT03875235) [113].”
InfluentialKelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00727-4 · Cited by 1,169 · cited 1×
“…III trials in advanced BTC patients showed that the addition of pembrolizumab to cisplatin/gemcitabine revealed an improvement in OS compared to cisplatin/gemcitabine alone without any new safety signals (mOS: 12·7 vs. 10·9 months; one-sided P = 0.0034 [significance threshold P = 0.02]) [110].”
InfluentialMechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066 · cited 1×
“Given their overexpression in various cancers, inhibiting these kinases offers a targeted therapeutic approach [41].”
Shen, D.-W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005637 · Cited by 955 · cited 2×
“Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10].”
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Rudin, C. M., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., Cheema, P. K., Rodriguez-Abreu, D., Wollner, M., Yang, J. C.-H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00793 · Cited by 760 · cited 1×
“Pem-brolizumab combined with platinum-etoposide demonstrated an ORR of 70.6% and a 12-month PFS of 13.6%, whilst durvalumab showed an ORR of 51.5% and mPFS of 6.1 months (NCT03066778 and NCT04712903) [103, 112].”
InfluentialA decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743 · cited 1×
“This class of drugs includes poly(ADP-ribose) polymerase (PARP) inhibitors that have received FDA approval [47, 48].”
Garassino, M. C., Gadgeel, S., Speranza, G., Felip, E., Esteban, E., Dómine, M., Hochmair, M. J., Powell, S. F., Bischoff, H. G., Peled, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01989 · Cited by 733 · cited 3×
“In the phase III KEYNOTE-189 trial of previously untreated metastatic Page 12 of 22 NSCLC patients, the addition of pembrolizumab to platinum/pemetrexed chemotherapy improved efficacy outcomes with manageable toxicity [100].”
InfluentialCancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 715 · cited 1×
“In addition to cytokines, cancer vaccines are emerging as promising immunotherapies, demonstrating a level of therapeutic efficacy that surpasses or equals that of other treatments in certain contexts, which is considered high relative to current standards of care [127].”
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00515-6 · Cited by 690
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Twomey, J. D., & Zhang, B. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00574-0 · Cited by 657 · cited 1×
“The subsequent triumphs in clinical trials paved the way for the approval of other anti-PD-1 mAbs, such as pembrolizumab, camrelizumab, sintilimab, toripalimab, and nivolumab, for treating a diverse range of malignancies [99].”
Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00152-2 · Cited by 643 · cited 1×
“…studies demonstrated that these combinations did not significantly improve efficacy or provide benefit beyond chemotherapy alone in patients with untreated extensive-stage SCLC [101], recurrent platinum-resistant ovarian cancer patients [105], or advanced urothelial carcinoma patients [106].”
Hanna, N., Johnson, D., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Giaccone, G., Hesketh, P. J., Jaiyesimi, I., Leighl, N. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.6065 · Cited by 643 · cited 1×
“Notably, paclitaxel (taxane), in combination with either cisplatin or carboplatin, was approved by FDA for treating patients with advanced ovarian cancer after initial surgery [22], and NSCLC [23, 24].”
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636 · cited 1×
“Amidst the evolving landscape of reformed and newly developed platinum drugs, multi-targeted platinum compounds have garnered considerable attention for their potential in cancer-specific therapy [154].”
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606 · cited 1×
“Anti-cancer monotherapies, whether broadly active cytotoxics or even the most effective molecularly targeted drugs, have limited ability to induce long-lasting clinical responses, as drug resistance is common [16].”
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Ready, N., Hellmann, M. D., Awad, M. M., Otterson, G. A., Gutierrez, M., Gainor, J. F., Borghaei, H., Jolivet, J., Horn, L., Mates, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01042 · Cited by 581 · cited 1×
“In another intriguing approach, anti-CTLA-4 mAb, ipilimumab, was added to nivolumab/platinum-doublet chemotherapy regimens where this combination was found effective and tolerable as a first-line treatment of advanced/metastatic NSCLC (NCT02659059) [114].”
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Poly(ADP-ribose) polymerase inhibition: past, present and future
Curtin, N. J., & Szabo, C. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0076-6 · Cited by 556 · cited 1×
“This class of drugs includes poly(ADP-ribose) polymerase (PARP) inhibitors that have received FDA approval [47, 48].”
Cisplatin nephrotoxicity: new insights and therapeutic implications
Tang, C., Livingston, M. J., Safirstein, R., & Dong, Z. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00631-7 · Cited by 548 · cited 1×
“However, despite being effective in numerous cases, cisplatin is linked to significant off-target toxicity, including nephrotoxicity, ototoxicity, and neurotoxicity [8].”
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540 · cited 1×
“Preclinical studies have shown that ada-vosertib, a potent and selective WEE1 inhibitor, enhances the efficacy of platinum chemotherapy, particularly in tumour protein p53 (TP53)-deficient tumours models [43].”
Metal-based anticancer chemotherapeutic agents
Muhammad, N., & Guo, Z. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.02.003 · Cited by 515 · cited 1×
“Many reviews have provided comprehensive perspectives on the use of platinum metallodrugs given as monotherapies [20, 21].”
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503 · cited 1×
“However, some tumours may evade treatment by using alternative pathways, necessitating a multi-targeted strategy to combat resistance [45, 46].”
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II
Calvert, A. H., Harland, S. J., Newell, D. R., Siddik, Z. H., Jones, A. C., McElwain, T. J., Raju, S., Wiltshaw, E., Smith, I. E., Baker, J. M., et al. (1982) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00257742 · Cited by 484 · cited 1×
“1) which was reported by Cleare and Hoeschele in 1973, and then gained FDA approval in 1989 [11].”
HER2 expression status in diverse cancers: review of results from 37,992 patients
Yan, M., Schwaederle, M., Arguello, D., Millis, S. Z., Gatalica, Z., & Kurzrock, R. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9552-6 · Cited by 483 · cited 1×
“Human epidermal growth factor receptor 2 (HER2) promotes cell growth and division, and is frequently overexpressed in various cancers, notably ovarian and breast carcinomas [68].”
Dagher, R. N., Cohen, M., Williams, G., Rothmann, M. D., Gobburu, J. V. S., Robbie, G. J., Rahman, A., Chen, G., Staten, A., Griebel, D. J., et al. (2002) · PubMed · Cited by 470
Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., Raghav, K. P. S., Iwasaki, M., Masci, P., Ramanathan, R. K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0270 · Cited by 468
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459 · cited 1×
“For example, pelareorep (REOLY-SIN), is an investigational novel oncolytic virus composed of a live, replication-competent, Reovirus Type 3 Dearing strain in a proprietary formulation [121].”
“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
Davis, A., Tinker, A. V., & Friedlander, M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.038 · Cited by 433 · cited 2×
“These patients typically have low response rates to further chemotherapy ( 15%), with a PFS of 3 to 4 months and a median survival of less than 1 year [81].”
Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy
Alcindor, T., & Beauger, N. (2011) · Current Oncology · doi:10.3747/co.v18i1.708 · Cited by 432
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394 · cited 1×
“…for each individual drug compared to when they are administered alone; (3) minimising the development of drug resistance or relapse; (4) achieving high cancer selectivity (cancer cell killing without affecting normal cells); and (5) expanding the range of treatment-responsive cancers [18, 19].”
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390 · cited 1×
“In early-phase trials involving patients with advanced solid tumours, NC-6004 demonstrated reduced nephrotoxicity compared to cisplatin alone [143].”
Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01204 · Cited by 364 · cited 1×
“Similarly, adding pertuzumab to trastuzumab and platinum-based chemotherapy conferred clinical benefits in patients with HER2-positive breast cancer [70].”
Janjigian, Y. Y., Maron, S. B., Chatila, W. K., Millang, B., Chavan, S. S., Alterman, C., Chou, J. F., Segal, M. F., Simmons, M. Z., Momtaz, P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30169-8 · Cited by 362
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Zhou, C., Wu, L., Fan, Y., Wang, Z., Liu, L., Chen, G., Zhang, L., Huang, D., Cang, S., Yang, Z., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.011 · Cited by 322
Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future
Sen, S., Won, M., Levine, M. S., Noh, Y., Sedgwick, A. C., Kim, J. S., Sessler, J. L., & Arambula, J. F. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00417d · Cited by 297 · cited 1×
“Platinum-based drugs have demonstrated potential to induce an anti-cancer immune response by promoting the recruitment and activation of immune cells [95, 96], thereby enhancing the efficacy of immunotherapies.”
Ioka, T., Kanai, M., Kobayashi, S., Sakai, D., Eguchi, H., Baba, H., Seo, S., Taketomi, A., Takayama, T., Yamaue, H., et al. (2023) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1219 · Cited by 249 · cited 2×
“Finally, in BTC, cisplatin-gemcitabine remains the standard first-line therapy, with mOS ranging from 12.6 to 13.5 months and mPFS of 5.5–7.4 months (NCT02182778) [30].”
InfluentialGuigay, J., Aupérin, A., Fayette, J., Saada-Bouzid, E., Lafond, C., Taberna, M., Geoffrois, L., Martin, L., Capitain, O., Cupissol, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30755-5 · Cited by 232
Pignata, S., Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8566 · Cited by 229 · cited 1×
“In ovarian cancer, carboplatin-based doublets remain the cornerstone of therapy, with paclitaxel-carboplatin showing robust survival outcomes across multiple phase III trials (mPFS 16.8–20.7 months, mOS up to 57.4 months; NCT00326456) [131].”
InfluentialLipoplatin Formulation Review Article
Stathopoulos, G. P., & Boulikas, T. (2012) · Journal of Drug Delivery · doi:10.1155/2012/581363 · Cited by 224 · cited 1×
“For example, Lipoplatin, a liposomal cisplatin formulation, which has reached phase III trials and demonstrated excellent encouraging anti-cancer efficacy in several tumour types, including lung, colon, gastric, and prostate cancers [142], although clinical adoption remains limited.”
Geyer, C. E., Sikov, W. M., Huober, J., Rugo, H. S., Wolmark, N., O’Shaughnessy, J., Maag, D., Untch, M., Golshan, M., Lorenzo, J. P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.01.009 · Cited by 221
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
Choy, H., Park, C., & Yao, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2176 · Cited by 217 · cited 1×
“1) was developed, exciting great interest due to its high oral availability such that it can be administered in pill form, greatly improving patient convenience and reducing health care costs [14, 15].”
Nanoparticle formulations of cisplatin for cancer therapy
Duan, X., He, C., Kron, S. J., & Lin, W. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1390 · Cited by 216
Antibody–drug conjugates: in search of partners of choice
Fuentes-Antrás, J., Genta, S., Vijenthira, A., & Siu, L. L. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.01.003 · Cited by 201 · cited 1×
“Thanks to the advances in synthetic chemistry, ADCs have been designed to comprise tumour-targeting mAbs linked to cytotoxic payloads via intricately designed chemical linkers, simultaneously enabling potent effectiveness and precise targeting, thereby expanding the therapeutic index [72].”
Owonikoko, T. K., Dahlberg, S. E., Sica, G. L., Wagner, L. I., Wade, J. L., Srkalovic, G., Lash, B. W., Leach, J. W., Leal, T. B., Aggarwal, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00264 · Cited by 185 · cited 1×
“Encouragingly, in patients with extensive-stage SCLC, the addition of veliparib to a cis-platin/etoposide regimen met its primary endpoint with improved mOS (10.2 vs. 8.9 months; one-sided P = 0.17) and ORR (71.9% vs. 65.6%; two-sided P = 0.57) compared to a placebo-treated group [55].”
InfluentialHDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer
Stronach, E. A., Alfraidi, A., Rama, N., Datler, C., Studd, J. B., Agarwal, R., Guney, T. G., Gourley, C., Hennessy, B. T., Mills, G. B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4111 · Cited by 176 · cited 1×
“Moreover, histone deacetylase (HDAC) expression was significantly increased in resistant tumours [86].”
Introduction: Metals in Medicine
Franz, K. J., & Metzler-Nolte, N. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00685 · Cited by 173 · cited 1×
“Amongst the established chemo-therapeutic agents, metallodrugs have been extensively used for cancer therapy where they offer versatile electronic and unique structural features [3–5].”
Satraplatin: leading the new generation of oral platinum agents
Bhargava, A., & Vaishampayan, U. N. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903362437 · Cited by 170 · cited 1×
“1) was developed, exciting great interest due to its high oral availability such that it can be administered in pill form, greatly improving patient convenience and reducing health care costs [14, 15].”
Noonan, A. M., Farren, M. R., Geyer, S. M., Huang, Y., Tahiri, S., Ahn, D., Mikhail, S., Ciombor, K. K., Pant, S., Aparo, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.66 · Cited by 166 · cited 1×
“In a randomised phase II trial, the combination of pelareorep with carboplatin/paclitaxel was safe but did not improve PFS in patients with metastatic pancreatic adenocarcinoma (NCT01280058) [123].”
Yousuf, I., Bashir, M., Arjmand, F., & Tabassum, S. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214104 · Cited by 166 · cited 1×
“Amongst the established chemo-therapeutic agents, metallodrugs have been extensively used for cancer therapy where they offer versatile electronic and unique structural features [3–5].”
Daugaard, G., Skoneczna, I., Aass, N., de Wit, R., Santis, M. D., Dumez, H., Marreaud, S. I., Collette, L., Lluch, J. R. G., Bokemeyer, C., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq575 · Cited by 163 · cited 1×
“These have been the focus of phase III clinical trials in patients with relapsed hodgkin's lymphoma (NCT00025636) [135, 136], and men with previously untreated germ cell cancer (NCT00003941) [137].”
Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma
Josting, A., Müller, H., Borchmann, P., Baars, J. W., Metzner, B., Döhner, H., Aurer, I., Smardova, L., Fischer, T., Niederwieser, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5771 · Cited by 163 · cited 1×
“These have been the focus of phase III clinical trials in patients with relapsed hodgkin's lymphoma (NCT00025636) [135, 136], and men with previously untreated germ cell cancer (NCT00003941) [137].”
Falvo, E., Tremante, E., Fraioli, R., Leonetti, C., Zamparelli, C., Boffi, A., Morea, V., Ceci, P., & Giacomini, P. (2013) · Nanoscale · doi:10.1039/c3nr04268e · Cited by 154 · cited 1×
“In addition, a novel ADC was synthesised incorporating ferritin-based nanoparticles where mAb Ep1 were conjugated to a single ferritin cage (Hft) encapsulating cisplatin [79].”
Karam, A., Ledermann, J. A., Kim, J.-W., Sehouli, J., Lu, K., Gourley, C., Katsumata, N., Burger, R. A., Nam, B.-H., Bacon, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx011 · Cited by 153 · cited 1×
“Notably, paclitaxel (taxane), in combination with either cisplatin or carboplatin, was approved by FDA for treating patients with advanced ovarian cancer after initial surgery [22], and NSCLC [23, 24].”
Cai, L., Xu, G., Shi, C., Guo, D., Wang, X., & Luo, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.044 · Cited by 151 · cited 1×
“In preclinical studies, various nanocarriers have also been utilised for dual-drug codelivery of cisplatin/paclitaxel including telodendrimers [148], polymeric micelles [149], and nano-structured lipid carriers [150, 151] as well as cisplatin/ doxorubicin combinations using hyaluronic acid micelles…”
Ahn, J., Miura, Y., Yamada, N., Chida, T., Liu, X., Kim, A., Sato, R., Tsumura, R., Koga, Y., Yasunaga, M., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.069 · Cited by 147
Zalba, S., Contreras-Sandoval, A. M., Haeri, A., ten Hagen, T. L. M., Navarro-Blasco, Í., Koning, G. A., & Garrido, M. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.271 · Cited by 129 · cited 1×
“5c, d) [78].”
Liu, B., Han, L., Liu, J., Han, S., Chen, Z., & Jiang, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s115136 · Cited by 129 · cited 1×
“…also been utilised for dual-drug codelivery of cisplatin/paclitaxel including telodendrimers [148], polymeric micelles [149], and nano-structured lipid carriers [150, 151] as well as cisplatin/ doxorubicin combinations using hyaluronic acid micelles [152], and mesoporous silica NPs (MSNs) [153].”
Oza, A. M., Estevez-Diz, M., Grischke, E.-M., Hall, M., Marmé, F., Provencher, D., Uyar, D., Weberpals, J. I., Wenham, R. M., Laing, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0219 · Cited by 129 · cited 1×
“The combination resulted in improved mPFS compared to placebo [7.9 vs. 7.3 months; two-sided P = 0.080, exceeding the established significance threshold ( P < 0.2)] [44], although it is important to note that TP53 mutation does not always equate to functional deficiency.”
InfluentialSubbiah, V., Grilley-Olson, J. E., Combest, A. J., Sharma, N., Tran, R. H., Bobe, I., Osada, A., Takahashi, K., Balkissoon, J., Camp, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1114 · Cited by 118
Griffith, D., Morgan, M. P., & Marmion, C. J. (2009) · Chemical Communications · doi:10.1039/b916715c · Cited by 109 · cited 1×
“6) [156].”
Cheng, H., Zhang, Z., Borczuk, A., Powell, C. A., Balajee, A. S., Lieberman, H. B., & Halmos, B. (2013) · Carcinogenesis · doi:10.1093/carcin/bgs393 · Cited by 99 · cited 1×
“Mechanistic studies indicate that platinum/PARPi synergy is associated with sustained DNA double-strand breaks (DSBs) leading to a significantly marked increase in apoptosis [49, 50].”
Bröckelmann, P. J., Müller, H., Casasnovas, O., Hutchings, M., von Tresckow, B., Jürgens, M., McCall, S. J., Morschhauser, F., Fuchs, M., Borchmann, P., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx072 · Cited by 97 · cited 1×
“These have been the focus of phase III clinical trials in patients with relapsed hodgkin's lymphoma (NCT00025636) [135, 136], and men with previously untreated germ cell cancer (NCT00003941) [137].”
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
Mateo, J., Ong, M., Tan, D. S. P., Gonzalez, M. A., & de Bono, J. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.177 · Cited by 96
Mahalingam, D., Fountzilas, C., Moseley, J., Noronha, N., Tran, H., Chakrabarty, R., Selvaggi, G., Coffey, M., Thompson, B., & Sarantopoulos, J. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3260-6 · Cited by 94
Yu, T., Li, Y., Gu, X., & Li, Q. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.532457 · Cited by 94 · cited 1×
“…also been utilised for dual-drug codelivery of cisplatin/paclitaxel including telodendrimers [148], polymeric micelles [149], and nano-structured lipid carriers [150, 151] as well as cisplatin/ doxorubicin combinations using hyaluronic acid micelles [152], and mesoporous silica NPs (MSNs) [153].”
Treatment Approaches for Platinum-Resistant Ovarian Cancer
St Laurent, J., & Liu, J. F. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01771 · Cited by 88
Dual-drug codelivery nanosystems: An emerging approach for overcoming cancer multidrug resistance
Gong, J., Shi, T., Liu, J., Pei, Z., Liu, J., Ren, X., Li, F., & Qiu, F. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114505 · Cited by 86
Prasad, C. B., Prasad, S. B., Yadav, S. S., Pandey, L. K., Singh, S., Pradhan, S., & Narayan, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-13232-3 · Cited by 84 · cited 1×
“Mechanistic studies indicate that platinum/PARPi synergy is associated with sustained DNA double-strand breaks (DSBs) leading to a significantly marked increase in apoptosis [49, 50].”
Moore, K. N., O'Malley, D. M., Vergote, I., Martin, L. P., Gonzalez-Martin, A., Malek, K., & Birrer, M. J. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.017 · Cited by 82 · cited 2×
“Early-phase trials incorporating agents like veliparib or gemcitabine have demonstrated response rates up to 45%, and mirvetuximab soravtan-sine has shown an ORR of 71% and mPFS of 15 months (NCT02606305) [73].”
Application of Artificial Intelligence In Drug-target Interactions Prediction: A Review
Liao, Q., Zhang, Y., Chu, Y., Ding, Y., Liu, Z., Zhao, X., Wang, Y., Wan, J., Ding, Y., Tiwari, P., et al. (2025) · npj Biomedical Innovations · doi:10.1038/s44385-024-00003-9 · Cited by 82
Garuti, L., Roberti, M., & Bottegoni, G. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867321666141216125528 · Cited by 81 · cited 1×
“However, some tumours may evade treatment by using alternative pathways, necessitating a multi-targeted strategy to combat resistance [45, 46].”
Gray, H. J., Bell‐McGuinn, K. M., Fleming, G. F., Cristea, M. C., Xiong, H., Sullivan, D. M., Luo, Y., McKee, M. D., Munasinghe, W. P., & Martin, L. P. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.12.029 · Cited by 77
Multifunctional platinum‐based nanoparticles for biomedical applications
Cheng, Q., & Liu, Y. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1410 · Cited by 76 · cited 1×
“Also, the tumour-localised drug delivery strategies exhibit benefits for preventing local tumour recurrence [141].”
The oncolytic virus, pelareorep, as a novel anticancer agent: a review
Chakrabarty, R., Tran, H., Selvaggi, G., Hagerman, A., Thompson, B., & Coffey, M. C. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0216-8 · Cited by 74 · cited 1×
“Preclinical data demonstrated that pelareorep induces antineoplastic activity across various cancers types, particularly in cells with an activated RAS-signalling pathway [122].”
Gibson, J., Alzghari, S. K., Ahn, C. W., Trantham, H., & La-Beck, N. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0126 · Cited by 71 · cited 1×
“Immunotherapies, particularly immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4, further potentiate the anti-cancer response by modulating the tumour microenvironment [26].”
Horinouchi, H., Nogami, N., Saka, H., Nishio, M., Tokito, T., Takahashi, T., Kasahara, K., Hattori, Y., Ichihara, E., Adachi, N., et al. (2021) · Cancer Science · doi:10.1111/cas.14980 · Cited by 71
Mahner, S., Meier, W., du Bois, A., Brown, C., Lorusso, D., Dell’Anna, T., Cretin, J., Havsteen, H., Bessette, P., Zeimet, A. G., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.11.017 · Cited by 70
Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr441 · Cited by 69
Fronik, P., Poetsch, I., Kastner, A., Mendrina, T., Hager, S., Hohenwallner, K., Schueffl, H. H., Herndler‐Brandstetter, D., Koellensperger, G., Rampler, E., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00770 · Cited by 67 · cited 1×
“For example, Fronik et al. developed a triple-action platinum(IV) prodrug, designed for tumour targeting via maleimide-mediated albumin binding, also for release of the immunomodulatory ligand 1-methyl-d-tryptophan (1-MDT) [155].”
Cisplatin and doxorubicin dual-loaded mesoporous silica nanoparticles for controlled drug delivery
Li, H., Yu, H., Zhu, C., Hu, J., Du, M., Zhang, F., & Yang, D. (2016) · RSC Advances · doi:10.1039/c6ra17213j · Cited by 57 · cited 1×
“…also been utilised for dual-drug codelivery of cisplatin/paclitaxel including telodendrimers [148], polymeric micelles [149], and nano-structured lipid carriers [150, 151] as well as cisplatin/ doxorubicin combinations using hyaluronic acid micelles [152], and mesoporous silica NPs (MSNs) [153].”
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
Yusoh, N. A., Ahmad, H., & Gill, M. R. (2020) · ChemMedChem · doi:10.1002/cmdc.202000391 · Cited by 57 · cited 1×
“This approach is best illustrated by encompassing inhibitors of key mediators of DNA repair alongside platinum drugs in various recurrent cancers (NCT01237067 and NCT01033292) [83, 84].”
Self-citationLee, J.-M., Peer, C. J., Yu, M., Amable, L., Gordon, N., Annunziata, C. M., Houston, N., Goey, A. K. L., Sissung, T. M., Parker, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1546 · Cited by 56 · cited 2×
“This approach is best illustrated by encompassing inhibitors of key mediators of DNA repair alongside platinum drugs in various recurrent cancers (NCT01237067 and NCT01033292) [83, 84].”
Yang, J., Ju, Z., & Dong, S. (2017) · Drug Delivery · doi:10.1080/10717544.2016.1236849 · Cited by 54 · cited 1×
“…also been utilised for dual-drug codelivery of cisplatin/paclitaxel including telodendrimers [148], polymeric micelles [149], and nano-structured lipid carriers [150, 151] as well as cisplatin/ doxorubicin combinations using hyaluronic acid micelles [152], and mesoporous silica NPs (MSNs) [153].”
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., et al. (2024) · Nature · doi:10.1038/s41586-024-07384-2 · Cited by 53
Cibula, D., Rob, L., Mallmann, P., Knapp, P., Klat, J., Chovanec, J., Minar, L., Melichar, B., Hein, A., Kieszko, D., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.07.003 · Cited by 52 · cited 1×
“Subsequently, the dendritic cell-based immunotherapy, DCVAC/OvCa, was combined with carboplatin/gemcitabine regimen in a phase II trial to evaluate their safety and efficacy in platinum-sensitive ovarian cancer (NCT02107950) [129].”
Griffith, D. M., Duff, B., Suponitsky, K. Y., Kavanagh, K. A., Morgan, M. P., Egan, D. A., & Marmion, C. J. (2011) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.03.001 · Cited by 51
Miller, K. D., Tong, Y., Jones, D. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1082 · Cited by 50 · cited 1×
“These preclinical data have prompted clinical trials to assess this combination in various advanced cancers including TNBC, ovarian, SCLC and head and neck squamous cell carcinoma (HNSCC) (NCT01074970, NCT01063816, NCT02032277, NCT01642251, NCT01711541, NCT02163694, and NCT03150576) [51–58].”
del Solar, V., & Contel, M. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2019.110780 · Cited by 50
Lin, C., Yang, S., Peng, C., & Shieh, M. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b13431 · Cited by 45 · cited 1×
“Moreover, another study developed oxaliplatin-loaded apoferritin conjugated with pani-tumumab via a polyethylene glycol (PEG) linker, which was designed to specifically target EGFR-overexpressing cell lines [80].”
Induction of targeted necrosis with HER2-targeted platinum( iv ) anticancer prodrugs
Wong, D. Y. Q., Lim, J. H., & Ang, W. H. (2015) · Chemical Science · doi:10.1039/c5sc00015g · Cited by 40 · cited 1×
“6) [160].”
Pérez-Ramírez, C., Cañadas-Garre, M., Alnatsha, A., Villar, E., Delgado, J. R., Faus-Dáder, M. J., & Calleja-Hernández, M. Ÿ. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.002 · Cited by 33 · cited 1×
“The variability in observed toxicity across studies can be attributed to differences in patient characteristics, treatment regimens, supportive care measures, and study designs [37, 38].”
Wirth, L. J., Dakhil, S. R., Kornek, G. V., Axelrod, R. S., Adkins, D. R., Pant, S., O’Brien, P. E., Debruyne, P. R., Oliner, K. S., Dong, J., et al. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.07.005 · Cited by 33
Doi, T., Hamaguchi, T., Shitara, K., Iwasa, S., Shimada, Y., Harada, M., Naito, K., Hayashi, N., Masada, A., & Ohtsu, A. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3254-4 · Cited by 33 · cited 1×
“It has been further investigated in clinical studies in combination with gemcitabine [144–146] and pembrolizumab [147].”
Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations
Meng, X., Gao, J. Z., Gomendoza, S. M. T., Li, J., & Yang, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.737951 · Cited by 33 · cited 1×
“A notable example of tyrosine kinase inhibitors (TKIs) are the WEE1 inhibitors, which regulate the G2/M transition and maintain genomic stability [42].”
Parker, J. P., Nimir, H., Griffith, D. M., Duff, B., Chubb, A. J., Brennan, M. P., Morgan, M. P., Egan, D. A., & Marmion, C. J. (2013) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2013.03.011 · Cited by 32 · cited 1×
“6) [157], showing similar cytotoxicity to Pt-malSAHA in A2780 ovarian cells and significant potency against cisplatin-resistant A2780cisR ovarian cancer cells.”
Forster, M. D., Dillon, M. T., Kocsis, J., Remenár, É., Pajkos, G., Rolland, F., Greenberg, J., & Harrington, K. J. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.017 · Cited by 32 · cited 2×
“Encouragingly, combinations with veliparib or HER-targeting agents like panitumumab and patritumab demonstrated mOS up to 13.5 months (NCT00454779, NCT02633800) [90, 133].”
InfluentialVolovăț, S. R., Ciuleanu, T., Koralewski, P., Olson, J. E. G., Croitoru, A. E., Koynov, K. D., Stabile, S., Cerea, G., Osada, A., Bobe, I., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27684 · Cited by 32 · cited 1×
“It has been further investigated in clinical studies in combination with gemcitabine [144–146] and pembrolizumab [147].”
Son, D. J., Hong, J. E., Ban, J. O., Park, J. H., Lee, H. L., Gu, S. M., Hwang, J. Y., Jung, M. H., Lee, D. W., Han, S., et al. (2015) · BioMed Research International · doi:10.1155/2015/397563 · Cited by 31
Wagner, D., Grabsch, H. I., Mauer, M. E. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.16_suppl.4057 · Cited by 30
Holloway, R. W., Thaker, P. H., Mendivil, A. A., Ahmad, S., Al‐Niaimi, A., BARTER, J. F., Beck, T. L., Chambers, S. K., Coleman, R. L., Crafton, S., et al. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-004812 · Cited by 29 · cited 1×
“…evidenced by a phase III clinical trial investigating the investigational oncolytic virus olvimulogene nanivacirepvec (Olvi-Vec) administered in combination with platinum-doublet chemotherapy and bevacizumab for the treatment of platinum-resistant or refractory ovarian cancer (NCT05281471) [130].”
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
Walsh, C. S., Kamrava, M., Rogatko, A., Kim, S., Li, A., Cass, I., Karlan, B., & Rimel, B. J. (2021) · PLOS ONE · doi:10.1371/journal.pone.0252665 · Cited by 27 · cited 2×
“This treatment also did not improve the durability of response in patients with platinum-resistant recurrent ovarian cancer compared to platinum chemotherapy alone, although the combination regimen was well tolerated with no discontinuations due to treatments-related toxicity [105].”
Liao, J. B., Gwin, W. R., Urban, R. R., Hitchcock-Bernhardt, K. M., Coveler, A. L., Higgins, D. M., Childs, J. S., Shakalia, H., Swensen, R. E., Stanton, S. E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003122 · Cited by 27
McNamara, M. G., Bridgewater, J., Palmer, D. H., Faluyi, O., Wasan, H., Patel, A., Ryder, W. D., Barber, S., Gnanaranjan, C., Ghazaly, E., et al. (2021) · The Oncologist · doi:10.1002/onco.13598 · Cited by 25 · cited 1×
“Interestingly, it was evaluated in combination with cisplatin in a phase Ib clinical trial in patients with locally advanced or metastatic BTC (NCT02351765) [29].”
Clarke, J. M., Patel, J. D., Robert, F., Kio, E. A., Thara, E., Camidge, D. R., Dunbar, M., Nuthalapati, S., Dinh, M. H., & Bach, B. A. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.09.004 · Cited by 25 · cited 1×
“Other trials also examined toripalimab (NCT04144608) [118], and nivolumab (NCT02944396) [119], in combination with platinum-based regimens in NSCLC patients.”
Koeneman, B. J., Schreibelt, G., Gorris, M. A. J., Hins - de Bree, S., Westdorp, H., Ottevanger, P. B., & de Vries, I. J. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368103 · Cited by 24 · cited 1×
“In a phase I/II study, the addition of dendritic cell vaccination to a carboplatin/paclitaxel regimen was safe and tolerable in patients with metastatic endometrial cancer (NCT04212377) [128].”
Thibault, C., Fléchon, A., Albiges, L. K., Joly, C., Barthélémy, P., Gross-Goupil, M., Chevreau, C., Coquan, E., Rolland, F., Laguerre, B., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.018 · Cited by 23
Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas
Paik, P. K., Luo, J., Ai, N., Kim, R. Y., Ahn, L. S. H., Biswas, A., Coker, C., Ma, W., Wong, P., Buonocore, D. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33719-6 · Cited by 22 · cited 1×
“The safety, efficacy, and pharmacodynamic effects of the addition of certolizumab, a TNF inhibitor, to cisplatin/pemetrexed regimen was evaluated in stage IV lung adenocarcinoma patients (NCT02120807) [126].”
Huang, R., Sun, Y., Zhang, X.-Y., Sun, B.-W., Wang, Q.-C., & Zhu, J. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.05.013 · Cited by 21 · cited 2×
“In HER2-positive SK-BR-3 cells, free oxaliplatin showed faster initial uptake, reaching 25 ng Pt per million cells at 4 h, approximately 1.7-fold higher than Herceptin-Pt(II) conjugate [75].”
InfluentialMondaca, S., Margolis, M., Sanchez-Vega, F., Jonsson, P., Riches, J. C., Ku, G. Y., Hechtman, J. F., Tuvy, Y., Berger, M. F., Shah, M. A., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-018-0861-7 · Cited by 21
Liskova, B., Zerzankova, L., Novakova, O., Kostrhunova, H., Travnicek, Z., & Brabec, V. (2012) · Chemical Research in Toxicology · doi:10.1021/tx200525n · Cited by 20 · cited 1×
“6), demonstrating cytotoxicity comparable to or greater than that of cisplatin against ovarian cells [159].”
Wirth, L. J., Dakhil, S. R., Kornek, G. V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.6029 · Cited by 20 · cited 1×
“Encouragingly, combinations with veliparib or HER-targeting agents like panitumumab and patritumab demonstrated mOS up to 13.5 months (NCT00454779, NCT02633800) [90, 133].”
InfluentialJelinek, M. J., Foster, N. R., Zoroufy, A. J., Schwartz, G. K., Munster, P. N., Seiwert, T. Y., de Souza, J. A., & Vokes, E. E. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105171 · Cited by 20 · cited 1×
“In addition, combining veli-parib with a carboplatin/paclitaxel regimen was found to be well tolerated in advanced HNSCC patients, with 2-year OS rate of 77.8% and 2-year PFS rate of 66.7% [56].”
InfluentialAyoub, J.-P., Wildiers, H., Friedlander, M., Arun, B. K., Han, H. S., Puhalla, S., Shparyk, Y., Jakobsen, E. H., Wu, M., Bach, B. A., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211059601 · Cited by 17 · cited 2×
“For example, veliparib with carboplatin and paclitaxel resulted in a mPFS of 16.6 months in TNBC patients (NCT02163694) [57].”
InfluentialPhase I trial of ribociclib with platinum chemotherapy in ovarian cancer
Coffman, L. G., Orellana, T. J., Liu, T., Frisbie, L. G., Normolle, D., Griffith, K., Uppal, S., McLean, K., Berger, J., Boisen, M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160573 · Cited by 17 · cited 1×
“Additionally, cyclin dependent kinases (CDKs) are also key regulators of DRR, which led to a phase I study examining the combination of ribocliclib, a CDK4/6 inhibitor, with carboplatin/paclitaxel in patients with recurrent platinum-sensitive ovarian cancer (NCT03056833) [85].”
Li, J., Li, Z., Li, M., Zhang, H., & Xie, Z. (2015) · Journal of Applied Polymer Science · doi:10.1002/app.41440 · Cited by 16 · cited 1×
“…various nanocarriers have also been utilised for dual-drug codelivery of cisplatin/paclitaxel including telodendrimers [148], polymeric micelles [149], and nano-structured lipid carriers [150, 151] as well as cisplatin/ doxorubicin combinations using hyaluronic acid micelles [152], and…”
Dillon, M. T., Grove, L., Newbold, K. L., Shaw, H., Brown, N. F., Mendell, J., Chen, S., Beckman, R. A., Jennings, A., Ricamara, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1539 · Cited by 16 · cited 2×
“A phase Ib trial showed patritu-mab plus cetuximab/platinum was tolerable and active in recurrent and/or metastatic HNSCC [89].”
Tjulandin, S., Fedyanin, M., Vladimirov, V. I., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5541 · Cited by 14
Colombo, N., Zaccarelli, E., Baldoni, A., Frezzini, S., Scambia, G., Palluzzi, E., Tognon, G., Lissoni, A. A., Rubino, D., Ferrero, A., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0584-5 · Cited by 14 · cited 1×
“…antibodies that target VEGF, also known as anti-angiogenesis agents, such as bevacizumab and ramucirumab, had undergone clinical investigations to determine their suitability as partners for platinum-based regimens (NCT00989651, NCT01160744, NCT01735071, NCT02359058, and NCT02363751) [64–67].”
Osada, A., Mangel, L., Fijuth, J., et al. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31164-3 · Cited by 14 · cited 1×
“It has been further investigated in clinical studies in combination with gemcitabine [144–146] and pembrolizumab [147].”
Sharma, P., Kimler, B. F., O'Dea, A., Nye, L. E., Wang, Y. Y., Yoder, R., Prochaska, L. H., Wagner, J. L., Amin, A. L., Larson, K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.516 · Cited by 13 · cited 3×
“Other regimens, such as carboplatin with docetaxel or with cyclophosphamide and doxorubicin, showed pCR rates between 52 and 55% (NCT02413320) [27].”
InfluentialMoore, K. N., Miller, A., Bell‐McGuinn, K. M., Schilder, R. J., Walker, J. L., O'Cearbhaill, R. E., Guntupalli, S. R., Armstrong, D. K., Hagemann, A. R., Gray, H. J., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.10.012 · Cited by 12
Ma, W. W., Zhu, M., Lam, E. T., Diamond, J. R., Dy, G. K., Fisher, G. A., Goff, L. W., Alberts, S., Bui, L. A., Sanghal, A., et al. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04235-z · Cited by 12 · cited 1×
“In an intriguing approach, a phase I study has investigated the combination of carboplatin with paclitaxel injection concentrate for nano-dispersion (PICN) in patients with advanced solid malignancies (ClinicalTri-als.gov Identifier: NCT01304303) [25].”
Christenson, E. S., Lim, S. J., Durham, J., De Jesus-Acosta, A., Bever, K., Laheru, D., Ryan, A., Agarwal, P., Scharpf, R. B., Le, D. T., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0343 · Cited by 12
Penson, R. T., Ambrosio, A. J., Whalen, C. A., Krasner, C. N., Konstantinopoulos, P. A., Bradley, C., Matulonis, U. A., & Birrer, M. J. (2023) · The Oncologist · doi:10.1093/oncolo/oyac275 · Cited by 12 · cited 1×
“…and is well tolerated in platinum-sensitive and -resistant recurrent ovarian cancer, particularly in patients with BRCA mutations (NCT01033123) [91]; however, given that iniparib is no longer considered a true PARPi and its mechanism of action remains unclear [92], the basis of this observed…”
Ahn, J., & Nagasaka, M. (2023) · Cancer Management and Research · doi:10.2147/cmar.s325856 · Cited by 12 · cited 1×
“Of note, the combination of cemiplimab-rwlc, mAb targeting PD-1, in combination with platinum-based chemotherapy has gained FDA approval as first-line treatment for adult patients with advanced NSCLC [120].”
Meteran, H., Knudsen, A. Ø., Jørgensen, T. L., Nielsen, D., & Herrstedt, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030897 · Cited by 12
Trieu, V., Pinto, H. A., Riess, J. W., Lira, R., Luciano, R., Coty, J., Boothroyd, D. B., & Colevas, A. D. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0618 · Cited by 10
Xu, N., Ying, K., Wang, Z., Liu, Y., Jiang, H., Zhou, H., & Wang, S. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e20546 · Cited by 10 · cited 2×
“In these patients, this combination showed good clinical efficacy (ORR: 68.4%, and mPFS: 11.4 months), with an acceptable safety profile [116].”
InfluentialBarber, E. L., Chen, S., Pineda, M. J., Robertson, S. E., Hill, E. K., Teoh, D., Schilder, J., O'Shea, K. L., Kocherginsky, M., Zhang, B., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0147 · Cited by 9 · cited 1×
“Notably, in patients with advanced endometrial cancer, the addition of pembrolizumab to carboplatin/paclitaxel was found to improve ORR and was well tolerated compared to the placebo/chemotherapy group (ORR: 74.4%; P = 0.001, and mPFS: 10.6 months) [108].”
InfluentialChin, A. I., Ly, A., Rodriguez, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.6_suppl.165 · Cited by 9
Wilbur, H. C., Durham, J. N., Lim, S. J., Purtell, K., Bever, K. M., Laheru, D. A., De Jesus-Acosta, A., Azad, N. S., Wilt, B., Diaz, L. A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0230 · Cited by 9 · cited 2×
“For this reason, a subsequent study was conducted to examine the addition of irinotecan to the cisplatin/gemcitabine/docetaxel/capecitabine regimen in patients with metastatic pancreatic cancer (NCT02324543) [31, 32].”
Yin, X., Zhuang, Y., Song, H., Xu, Y., Zhang, F., Cui, J., Zhao, L., Yu, Y., Zhang, Q., Ye, J., et al. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.11.002 · Cited by 9 · cited 2×
“4c) [76].”
Influentialde Jong, C., Herder, G. J. M., & Deneer, V. H. M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13683 · Cited by 8
Tan, Y. Y., Al-Bubseeree, B., Irvine, D. A., MacDonald, G., McQuaker, G., Parker, A. N., Waterston, A. M., & White, J. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.11.013 · Cited by 6 · cited 1×
“…in the cisplatin/cytotoxic regimen demonstrated clinical benefits, with a 2-year PFS rate of 67% and a 2-year OS rate of 72% (NCT02375204) [138], indicating potential for regulatory approval and broader clinical application, albeit with the need for careful patient selection and…”
Drewett, L., Lucey, R., Pinilla, K. A., Grybowicz, L., Wulff, J., Dayimu, A., Demiris, N., Vallier, A.-L., Qian, W., Machin, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.tps619 · Cited by 6 · cited 2×
“For instance, neoadjuvant paclitaxel plus carbo-platin achieved a pCR of 52% and a 36-month EFS of 79% in the PARTNER trial (NCT03150576) [58, 59].”
Lee, D. H., Kim, H. R., Keam, B., Kato, K., Kuboki, Y., Gao, H., Yovine, A., Robbins, S. H., & Ahn, M. (2023) · Cancer Medicine · doi:10.1002/cam4.6260 · Cited by 6
Grossi, F., Jaśkiewicz, P., Ferreira, M., Czyżewicz, G., Kowalski, D., Ciuffreda, L., Garcia-Gomez, R., Caruso, S., Bosch-Barrera, J., Gautier, S., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211022905 · Cited by 5 · cited 1×
“Similarly, cisplatin combined with the vinca alkaloid vinorelbine has shown efficacy and tolerability as a first-line therapy in NSCLC patients, with an OS of 10.2 months and an acceptable safety profile (EudraCT number: 2012–003531-40) [36].”
InfluentialZhang, Y., Zeng, L., Zhang, X., Zhou, Y., Zhang, B., Jiang, W., Yang, N., & Zhou, C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.339 · Cited by 5
Cervantes, A. M. R., Hoskins, P. J., Vergote, I. B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.5502 · Cited by 4
Spigel, D. R., Hainsworth, J. D., Shipley, D. L., Mekhail, T. M., Zubkus, J. D., Waterhouse, D. M., Daniel, D. B., Burris, H. A., & Greco, F. A. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.007 · Cited by 4
Isla, D., Arriola, E., Garcia Campelo, M. R., Diz Tain, P., Marti Blanco, C., Lopez-Brea Piqueras, M. M., Moreno Vega, A. L., Leon Mateos, L. A., Oramas Rodriguez, J. M., Gutierrez Calderon, V., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.1627 · Cited by 4
Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer
Li, J., Hu, H., He, J., Hu, Y., Liu, M., Cao, B., Chen, D., Ye, X., Zhang, J., Zhang, Z., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101825 · Cited by 4 · cited 1×
“This was shown by Li et al. in ovarian cancer models, where sequential administration of carboplatin and cell division cycle 7-related protein kinase (CDC7) inhibitor, XL413, showed synergistic enhancement of apoptosis [93].”
Thomas, S. G., Doebele, R. C., Spigel, D. R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx091.039 · Cited by 3
Koczywas, M., Frankel, P. H., Riess, J. W., El-Khoueiry, A. B., Villaruz, L. C., Leong, S., Ruel, C., Synold, T. W., O'Connor, T., & Newman, E. M. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9055 · Cited by 2 · cited 1×
“…complementary mechanisms of action, the combined use of methoxyamine, a base excision repair (BER) inhibitor, with cisplatin/pemetrexed has shown promising anti-tumour effects, notably in salivary gland tumours, whilst maintaining a tolerable safety profile at the tested doses (NCT02535312) [60].”
Menis, J., Bironzo, P., Radj, G., Greillier, L., Monnet, I., Livi, L., Young, R., Decroisette, C., Cloarec, N., Robinet, G., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.494 · Cited by 2 · cited 1×
“…studies demonstrated that these combinations did not significantly improve efficacy or provide benefit beyond chemotherapy alone in patients with untreated extensive-stage SCLC [101], recurrent platinum-resistant ovarian cancer patients [105], or advanced urothelial carcinoma patients [106].”
Cited by
Key Nano-Strategies for Cisplatin Resistance in Advancing Anti-Cancer Therapy
Lei, S.-Y., Qin, H., Liu, S., & Sheng, J. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s551752 · Cited by 11
Kono, H., Kinjyo, S., Uyama, R., Fujita, S., Murayama, Y., & Ikematsu, S. (2025) · Gels · doi:10.3390/gels12010005 · Cited by 8
“CBP inhibits DNA synthesis during cancer cell division, thereby suppressing cell proliferation and inducing apoptosis [26,27].”
Gudasi, S., Kumar, D., Tewari, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-33214-0 · Cited by 4
Understanding Non-Small-Cell Lung Cancer: Biology, Therapeutics and Drug Resistance
Ahluwalia, P. K., Kolhe, R. B., & Rojiani, M. V. (2026) · Biomedicines · doi:10.3390/biomedicines14010193 · Cited by 5
“Platinum-based chemotherapy remains central in NSCLC treatment, alone or in combination [12].”
Lanthanide Nanotheranostics in Radiotherapy
Han, S., Liu, Y., Cai, T., Liu, Y., & Ge‐Zhang, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010426 · Cited by 5
Metadata
- Authors
- Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R.
- Affiliations
- Sichuan University (CN)
- Universiti Putra Malaysia (MY)
- University of Oxford (GB)
- Swansea University (GB)
- Corresponding author
- Gill, Martin R.
- Venue
- Medical Oncology
- Published
- 2025-06-16
- Volume
- 42
- Issue
- 7
- Pages
- 262-262
- ISSN
- 1357-0560 (ISSN-L)
- 1559-131X
- PMC
- PMC12167724
- OpenAlex
- W4411321113
- Semantic Scholar
- 1c906ad91a2fd4884c7cd22cf4ea13e39d8daa11
- Cited by
- 40
- References
- 166
- Citations by year
- 2026: 32 · 2025: 8
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Medical Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- platinum-based chemotherapy, platinum resistance, combination therapy, targeted therapy, immunotherapy, antibody-drug conjugates, drug stability, biomarkers, toxicity management, ovarian cancer, non-small cell lung cancer, testicular cancer
- MeSH terms
- Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasms, Organoplatinum Compounds, Platinum Compounds, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.